Fulgent Genetics to acquire select assets of Bako Diagnostics and StrataDx for $55.5m

Bako and StrataDx are backed by Consonance Capital.

23 December 2025•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.